Phytobacterium plantarum and application thereof in preparation of gamma-aminobutyric acid and improvement of sleep
By optimizing the fermentation process of Lactobacillus plantarum XBMU-SN-23 to prepare γ-aminobutyric acid (GABA), the problems of side effects and insufficient purity of GABA synthesis in existing insomnia drugs have been solved, achieving safe and effective sleep improvement.
Patent Information
- Application Number
- CN202512047510.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-31
- Publication Date
- 2026-04-10
AI Technical Summary
Existing medications for treating insomnia have significant side effects, such as daytime sleepiness, impaired coordination, and drug dependence. Furthermore, current GABA synthesis methods suffer from harsh reaction conditions and insufficient product purity. There is an urgent need for a safe and effective natural method to improve sleep.
Using a strain of Lactobacillus plantarum XBMU-SN-23, γ-aminobutyric acid (GABA) was prepared by fermentation in a specific culture medium. The fermentation conditions were optimized to increase the yield, and the product was prepared into food, feed additives or drugs for improving sleep.
It significantly improves sleep quality in insomnia mice by regulating neurotransmitter systems such as GABA, 5-HT, IL-1, and MT, increasing sleep duration, repairing hippocampal damage, regulating the expression of related receptor proteins, and alleviating insomnia symptoms.
Smart Images

Figure CN121825807A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the field of biotechnology, in particular to a plant lactobacillus and its application in preparation of gamma-aminobutyric acid and improvement of sleep. BACKGROUND
[0002] Sleep is a regular and recurring physiological process of the body, which is essential for maintaining life and daily physiological functions. When the sleep-wake regulation mechanism of the human body is abnormal due to various factors, sleep disorders will occur. The main clinical manifestations of this disorder include insufficient or excessive sleep time, which can cause a series of diseases closely related to sleep and wakefulness. About 1 / 3 of the world's adults suffer from at least one sleep disorder. The problem of sleep disorders needs to be solved urgently.
[0003] Currently, the drugs for treating insomnia include benzodiazepines (alprazolam and diazepam), benzodiazepine receptor agonists (eszopiclone), ramelteon (a melatonin receptor agonist), etc. They exert their effects by enhancing the action of gamma-aminobutyric acid (GABA) neurotransmitters in the brain. However, these drugs have significant side effects. For example, these drugs can cause daytime sleepiness, affect coordination and balance, and long-term use can lead to drug dependence and tolerance. Due to the many disadvantages of these synthetic drugs, there is an increasing demand for natural therapies for treating insomnia.
[0004] In the study of natural active ingredients, the sleep-regulating effect of gamma-aminobutyric acid (GABA) has attracted much attention. As the most abundant inhibitory neurotransmitter in the central nervous system, GABA can inhibit the overexcitation of nerve cells, reduce anxiety, and induce sedation and improve sleep quality by binding to GABA receptors in the brain. Currently, the synthesis of GABA mainly includes chemical synthesis, plant extraction, and microbial fermentation. However, chemical synthesis and plant extraction have problems such as harsh reaction conditions and insufficient product purity. In microbial fermentation, lactic acid bacteria, as a recognized safe microorganism, have mild fermentation conditions, high product purity, and can naturally synthesize GABA during metabolism without the need for complex subsequent separation and purification processes, reducing production difficulty and cost. In addition, GABA-producing lactic acid bacteria also have the functions of regulating intestinal flora structure balance and repairing intestinal barrier function, and further regulating central nervous sleep through the "gut-brain axis". Therefore, GABA-producing lactic acid bacteria are ideal substances for naturally improving sleep, and have great research value and application potential. SUMMARY
[0005] The present application aims to at least solve one of the technical problems in the prior art, and provides a plant lactobacillus and its application in preparation of gamma-aminobutyric acid and improvement of sleep.
[0006] The technical solution of the present invention is as follows: The first aspect of the present invention provides a strain of *Lactobacillus plantarum* XBMU-SN-23, wherein *Lactobacillus plantarum* ( Lactiplantibacillus plantarum XBMU-SN-23 was deposited on December 19, 2025, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 37118. The deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing.
[0007] In one embodiment of the present invention, the survival rate of *Lactobacillus plantarum* XBMU-SN-23 after culturing at pH 2.0 for 24 h was 65.42%, and the survival rate after culturing at 0.5% bile salt concentration for 24 h was 79.8 ± 2.83%.
[0008] In one embodiment of the present invention, the *Lactobacillus plantarum* XBMU-SN-23 is milky white, with a raised center, smooth surface, and neat edges.
[0009] A second aspect of the invention provides the use of the aforementioned *Lactobacillus plantarum* XBMU-SN-23 in the preparation of γ-aminobutyric acid (GABA).
[0010] A third aspect of the present invention provides a fermentation broth containing γ-aminobutyric acid (GABA), wherein the method for preparing the fermentation broth containing GABA includes: The *Lactobacillus plantarum* XBMU-SN-23 was inoculated into a culture medium containing Tween 80 and Mg. 2+ and Ca 2+ In the culture medium, the inoculum size of Lactobacillus plantarum XBMU-SN-23 was 1.5%~3.5%, the initial fermentation pH was 4.0~6.0, the fermentation temperature was 35℃~40℃, and the fermentation time was 12h~60h. After fermentation, the supernatant was collected by centrifugation to obtain the fermentation broth containing γ-aminobutyric acid.
[0011] In one embodiment of the present invention, the amount of Tween 80 added to the culture medium is 0.4% v / v to 0.6% v / v, and Mg... 2+ Concentrations range from 0.1 mg / mL to 0.3 mg / mL, Ca 2+ The concentration is 5~15 g / mL.
[0012] The fourth aspect of the invention provides the use of the aforementioned *Lactobacillus plantarum* XBMU-SN-23 or the aforementioned fermentation broth containing γ-aminobutyric acid in the preparation of products for improving sleep and / or preventing and / or treating insomnia.
[0013] In one embodiment of the present invention, the oral dose of the product, calculated based on the γ-aminobutyric acid contained therein, is 80 mg to 100 mg of γ-aminobutyric acid per kg body weight.
[0014] In one embodiment of the present invention, the product for improving sleep and / or preventing and / or treating insomnia has at least one of the following functions: 1) Increases the level of γ-aminobutyric acid in serum; 2) Increase serum MT levels; 3) Increases the level of serotonin in brain tissue; 4) Increase the level of interleukin-1 in brain tissue; 5) Reduce serum glutamate levels; 6) Reduces the dopamine content in brain tissue.
[0015] In one embodiment of the present invention, the product for improving sleep and / or preventing and / or treating insomnia has at least one of the following functions: 1) Increase 5-HT levels in brain tissue 1A The content; 2) Increase GABA levels in brain tissue A R α1 The content; 3) Increases GABA levels in brain tissue A R γ2 The content of.
[0016] A fifth aspect of the present invention provides a product for improving sleep and / or preventing and / or treating insomnia, the active ingredient of the product comprising the aforementioned *Lactobacillus plantarum* XBMU-SN-23 or the aforementioned fermentation broth containing γ-aminobutyric acid.
[0017] In one embodiment of the present invention, the product includes food, feed additives, or pharmaceuticals.
[0018] In an embodiment of the product described in this invention, the food is a solid beverage containing *Lactobacillus plantarum* XBMU-SN-23 or its metabolite GABA.
[0019] As an embodiment of the product described in this invention, the feed additive contains *Lactobacillus plantarum* XBMU-SN-23 or its metabolite GABA, as well as other excipients.
[0020] As an embodiment of the product described in this invention, the drug dosage form includes granules, capsules, tablets, oral liquids, etc.
[0021] This invention has at least one of the following beneficial effects: 1. This invention screened 12 strains of lactic acid bacteria from Lanzhou fermented vegetable juice, pickled vegetables, and yogurt. Six strains from different sources were screened through physiological and biochemical tests. Qualitative and quantitative measurements of these six strains ultimately identified a strain with high GABA-producing capacity, which was then identified as *Lactobacillus plantarum*. Lactiplantibacillus plantarum Studies have shown that this strain not only exhibits good acid and bile salt tolerance but also produces GABA. *Lactobacillus plantarum* XBMU-SN-23 and its metabolite GABA significantly improved sleep quality in insomnia-prone mice by upregulating GABA, 5-HT, IL-1, and MT, downregulating Glu and DA, and regulating 5-HT. 1A receptors, GABA A R α1 and GABA A R γ2 The expression of receptor proteins regulates the neurotransmitter system, thereby improving sleep quality.
[0022] 2. This invention also provides optimization of the components of the culture medium for GABA production by Lactobacillus plantarum XBMU-SN-23 and optimization of fermentation conditions. Parameter optimization is carried out from two aspects to improve the GABA content produced by Lactobacillus plantarum XBMU-SN-23.
[0023] 3. This invention uses a typical PCPA-induced insomnia mouse model for experiments and found that the fermentation broth of *Lactobacillus plantarum* XBMU-SN-23 can significantly improve the sleep quality of insomnia mice. Specifically, compared with the model group, control group, blank group, and different fermentation broth dosage groups: (1) Except for the blank group, there was no significant difference in body weight among the groups. p >0.05), the mean weight of the blank group was the highest, at 35.20±0.40 g, and the brain index was higher than that of other groups. The final weight was the lowest in the positive control group, at only 31.47±0.15 g, followed by the model group, with a final weight of 32.20±0.17 g. The model group had the lowest brain index. Different doses of XBMU-SN-23 fermented liquid significantly increased weight, and the brain index increased to varying degrees. This indicates that XBMU-SN-23 fermented liquid can effectively treat the organ pathological changes caused by PCPA and DZP, and alleviate organ degeneration in PCPA-induced insomnia mice to a certain extent. (2) Compared with the model group, the sleep rate of each group increased significantly ( p <0.05), different dose groups all prolonged sleep time to varying degrees, among which 90 mg / kg XBMU-SN-23 fermentation broth significantly enhanced the hypnotic effect of sodium pentobarbital; (3) Compared with the control group, the IL-1 in the hypothalamus of the medium-dose XBMU-SN-23 fermentation broth was significantly increased. IL-1 is a cytokine with immunomodulatory effects and is also the earliest discovered cytokine with sleep-inducing effects. This indicates that XBMU-SN-23 fermentation broth can regulate sleep by causing an increase in IL-1. (4) Compared with the control group, the DA content of mice in the model group increased significantly, while the DA content in the control group and the low-dose group decreased, but the change in the medium-dose group was not obvious. This result indicates that the XBMU-SN-23 fermentation broth has a certain restorative effect on neurotransmitters, and it is speculated that the sleep-promoting effect may be achieved by regulating the 5-HT content.
[0024] (5) Compared with the control group, the BDNF content in the model group was significantly reduced, while it increased to varying degrees in the XBMU-SN-23 strain fermentation broth group, with the BDNF content in the medium-dose group being significantly increased. This indicates that the XBMU-SN-23 fermentation broth can play a good role in promoting sleep by increasing the content of BDNF cytokines; (6) Compared with the model group, the serum GABA and MT content of insomnia mice in different doses of XBMU-SN-23 fermentation broth groups increased significantly, while the Glu content decreased significantly, indicating that XBMU-SN-23 fermentation broth can alleviate insomnia by regulating monoamine substances and excitatory neurotransmitters in serum. (7) Compared with the model group, the hypothalamic nerve cells in the blank group were abundant, intact, and evenly distributed. In contrast, the hypothalamic nerve cells in the model group were loosely arranged, severely deformed, and contained a large number of fragmented cells. The cells in the different dose groups were neatly arranged, and the damage to atrophied cells was significantly repaired, indicating that the GABA-rich XBMU-SN-23 fermentation broth can improve hippocampal damage in PCPA-induced insomnia mice and thus improve sleep. (8) Compared with the blank group, the 5-HT in the brain tissue of mice in the model group was significantly higher. 1A and GABA A R α1 Receptor protein levels were significantly downregulated, while 5-HT levels were significantly upregulated in different dose groups. 1A Protein expression levels were observed. Medium-dose GABA significantly upregulated these levels, indicating that the XBMU-SN-23 fermentation broth has a mechanism for regulating sleep disorders in PCPA-induced insomnia mice. Therefore, the GABA-producing Lactobacillus plantarum XBMU-SN-23 of the present invention has broad prospects in products for prevention, relief, improvement and treatment. Attached Figure Description
[0025] Figure 1The images show the identification results of the screened strain XBMU-SN-23, including (a) a morphological observation of strain XBMU-SN-23; (b) a Gram staining image of strain XBMU-SN-23; and (c) a phylogenetic diagram of strain XBMU-SN-23. Figure 2 This is a graph showing the acid and bile salt tolerance of strain XBMU-SN-23; Figure 3 This is a graph showing the results of single-factor optimization of the process for different components of the culture medium for the strain; Figure 4 These are response surfaces and contour plots of different components of the culture medium for the strain; Figure 5 This is a graph showing the results of single-factor optimization of fermentation processes under different conditions; Figure 6 These are response surfaces and contour plots for different fermentation conditions; Figure 7 This is a graph showing the results of the XBMU-SN-23 fermentation broth on the levels of hypothalamic-related factors in PCPA-induced insomnia mice; Figure 8 This is a graph showing the results of XBMU-SN-23 fermentation broth on the serum levels of related factors in PCPA-induced insomnia mice; Figure 9 This is a diagram showing the pathological changes in the hippocampal tissue of PCPA-induced insomnia mice after XBMU-SN-23 fermentation broth treatment. Figure 10 This is a diagram showing the pathological changes in the hypothalamus tissue of PCPA-induced insomnia mice after XBMU-SN-23 fermentation broth treatment. Figure 11 This is a graph showing the results of Western blot analysis of the expression levels of related proteins in the mouse hypothalamus. Detailed Implementation
[0026] To make the technical problems solved, the technical solutions, and the beneficial effects of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and are not intended to limit the invention.
[0027] The healthy SPF-grade male KM mice involved in the following examples were purchased from the Experimental Animal Center of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. The ELISA kits for related inflammatory factors were purchased from Shanghai Enzyme-Linked Biotechnology Co., Ltd., and the BCA protein quantitative detection kits were purchased from Wuhan Saive Biotechnology Co., Ltd.
[0028] Example 1: Screening and identification of Lactobacillus plantarum XBMU-SN-23 (1) Screening of strain XBMU-SN-23: Samples from different sources were collected, including Lanzhou fermented vegetable juice, pickled vegetables, and yogurt. Accurately pipette 0.5 mL of samples from different sources and add them to 4.5 mL of sterile physiological saline. After shaking well, perform serial dilutions sequentially. Spread 200 μL of each serially diluted sample evenly onto MRS solid medium, with three replicates for each gradient. Place the spread medium in an incubator and incubate at 37°C for 48 h. After 48 h of incubation, select morphologically sound single colonies and streak them for another 48 h to obtain purified single strains. Label and record the single colonies, then inoculate them into MRS broth medium and incubate at 37°C for 24 h. After 2-3 subcultures, select strains for smear and microscopic examination, resulting in the selection of 12 lactic acid bacteria strains.
[0029] Physiological and biochemical tests were conducted, and six strains with better physiological and biochemical properties were selected from 12 lactic acid bacteria strains. They were numbered XBMU-JE-15, XBMU-JE-16, XBMU-M-12, XBMU-SN-23, XBMU-B-03, and XBMU-YD-22, respectively.
[0030] The yield of γ-aminobutyric acid (GABA) produced by each strain was further qualitatively and quantitatively determined by thin-layer chromatography and high-performance liquid chromatography, respectively. Among them, strain XBMU-SN-23, which was cultured from the sample of Lanzhou slurry, produced the highest yield of GABA.
[0031] (2) Identification of strain XBMU-SN-23:
[0032] The sequencing results were compared with the Genbank database of the National Center for Biotechnology Information (NCBI) using BLAST, and a phylogenetic tree was constructed using MEGA 11.0. The results showed that this strain is related to *Lactobacillus plantarum* (…). Lactiplantibacillus plantarum The nucleic acid sequence similarity of K-D513 was as high as 99%, and it was named *Lactobacillus plantarum* XBMU-SN-23. The results are as follows... Figure 1 As shown, where Figure 1 (a) is a morphological observation of strain XBMU-SN-23. It can be seen that the strain is milky white, with a raised center, smooth surface and neat edges. Figure 1 (b) Gram staining image of strain XBMU-SN-23; Figure 1 (c) is a phylogenetic diagram of strain XBMU-SN-23.
[0033] Example 2: Analysis of the growth characteristics of lactic acid bacteria strains (1) Growth curve and acid production determination: Six activated strains from Example 1 were inoculated into 10 mL of liquid culture medium at a 2% inoculation rate and cultured at 37°C. Samples were taken every 2 hours. The absorbance at 600 nm and pH value were measured with the culture time as the x-axis. The growth curve and acid production capacity curve of the strains were plotted.
[0034] (2) In vitro acid resistance test: The pH of the MRS liquid medium was adjusted to 2.0 and 4.0 with 1 mol / L HCl solution. The optimal growth strain in the logarithmic growth phase was inoculated at a rate of 2%, thoroughly mixed, and cultured in a 37℃ oven for 24 h. The absorbance was measured at 600 nm using a UV spectrophotometer, and the survival rate of the strain in the medium at different pH values was calculated.
[0035] The results are as follows Figure 2 As shown in (a), strain XBMU-SN-23 exhibits the strongest acid resistance at pH 2, with a survival rate of 65.42%.
[0036] Its survival rate formula is: Where K is the strain survival rate (%); A x A1 is the absorbance value of strain x at 600 nm; A2 is the absorbance value of strain 0 at 600 nm.
[0037] (3) In vitro bile salt tolerance test: The strains that grow optimally in the logarithmic growth phase were inoculated at a rate of 2% into MRS liquid medium with bile salt concentrations of 3% and 5%, respectively. After shaking and mixing, the cultures were incubated at 37°C for 24 h. The absorbance values were then measured at 600 nm using a UV spectrophotometer to calculate the growth rate of the strains in the medium at different bile salt concentrations. The calculation formula is the same as above.
[0038] The results are as follows Figure 2 As shown in (b), strain XBMU-SN-23 exhibited the highest bile tolerance at a bile salt concentration of 0.3%, with a survival rate of (74±2.95)%. At a bile salt concentration of 0.5%, the survival rate of strain XBMU-SN-23 was (79.8±2.83)%, which was higher than that at a bile salt concentration of 0.3%.
[0039] Example 3: Effects of different components of the culture medium on GABA production by strain XBMU-SN-23 (1) Single-factor experiment on the effect of different components of culture medium on GABA production by strain XBMU-SN-23: Using MRS as the basic culture medium (pH 4.8 substrate buffer), different concentrations of Tween 80 (0.2, 0.4, 0.6, 0.8, 1.0 %v / v), MgSO4 (0, 0.1, 0.2, 0.3, 0.4 mg / mL), MnSO4 (0, 0.02, 0.04, 0.06, 0.08 mg / mL), and CaCl2 (0, 5, 10, 15, 20 g / mL) were used for fermentation for 24 h to investigate the effects of each factor on GAD enzyme activity and GABA production.
[0040] The results are as follows Figure 3 As shown, glutamate decarboxylase (GAD) activity is positively correlated with GABA production. Tween80 exhibits the highest GAD activity at a concentration of 0.4% (v / v), reaching 50.61 ± 0.016 U / mL, at which point GABA production is 2.41 ± 0.029 g / L; Mg 2+ The addition of [a specific ingredient] can effectively improve the efficiency of GABA production by the strain, and the optimal addition level is 0.1 mg / mL, at which the GAD enzyme activity is 42.61±0.03 U / mL and the GABA yield is 2.03±0.03 g / L; the addition of Ca [a specific ingredient] can also improve the efficiency of GABA production by the strain. 2+ It can not only activate GAD enzyme activity, but also regulate its gene expression to biosynthesize GAD, in the process of microbial fermentation. 2+ The optimal concentration of the metal additive is 5 g / mL, at which the GAD enzyme activity is highest (42.58 ± 0.18 U / mL) and the GABA yield is 2.027 ± 0.07 g / L; while Mn 2+As a metal inhibitor, it suppressed GABA synthesis and GAD enzyme activity. That is, within the studied concentration range, the metal reagent additives MgSO4 and CaCl2 did not significantly affect the efficiency of GABA production by *Lactobacillus plantarum* XBMU-SN-23, while Mn... 2+ This significantly inhibited the enzyme activity of GAD.
[0041] (2) Optimization of the response surface methodology of different culture medium components to GABA production by strain XBMU-SN-23: A three-factor, three-level response surface methodology was used, with Tween 80 concentration (X1), MgSO4 concentration (X2), and CaCl2 concentration (X3) as the experimental influencing factors and GABA yield as the result. The interaction results among different factors were analyzed to optimize the fermentation conditions.
[0042] The results are as follows Figure 4 As shown, by Figure 4 It can be seen that the concentration of Tween 80 added to the culture medium is 0.47% (v / v), and Mg... 2+ The concentration was 0.18 mg / mL, Ca 2+ The concentration was 9.13 g / mL, while the theoretical value of GABA was 2.614 g / L.
[0043] Example 4: Optimization of fermentation conditions for GABA production by Lactobacillus plantarum XBMU-SN-23 (1) Single-factor experiment on fermentation conditions for GABA production by Lactobacillus plantarum XBMU-SN-23: Using MRS liquid fermentation medium (containing 1.5% L-Glu) as the basal medium, different inoculum concentrations (1.5%, 2.0%, 2.5%, 3.0%, 3.5%), different initial pH values (4.0, 4.5, 5.0, 5.5, 6.0), and different fermentation times (12 h, 24 h, 36 h, 48 h, 60 h) were selected. After incubation at 37℃, the mixture was centrifuged at 8000 r for 10 min, and the supernatant was collected. The GABA yield was determined by HPLC. Each group was repeated three times, and the average value was taken. The results are as follows: Figure 4 .
[0044] (2) Response surface methodology optimization of fermentation conditions for GABA production by Lactobacillus plantarum XBMU-SN-23: Based on the results of previous single-factor experiments, a three-factor, three-level experiment was designed with GABA yield (y) as the response value and pH, inoculum size, and fermentation time as independent variables (x). The Box-Behnken response surface methodology was used for optimization.
[0045] like Figure 5~Figure 6As shown, the results indicate that the optimal fermentation conditions were determined through single-factor experiments and a three-factor, three-level response surface methodology. The highest GABA yield of 3.562 g / L was achieved at an initial pH of 5.41, an inoculum size of 2.78%, and a fermentation time of 38.8 h. Compared to the initial GABA production by XBMU-SN-23, the γ-aminobutyric acid (GABA) yield increased from 2.150 g / L to 3.562 g / L, representing a 65.7% increase.
[0046] Example 5: Sleep-improving effect of XBMU-SN-23 strain fermentation broth on PCPA-induced insomnia in mice. The specific steps are as follows: Sixty healthy SPF-grade male KM mice (20-23g, 5 weeks old) were purchased from the Experimental Animal Center of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, license number: SCXK(Gan)2020-0002. After one week of acclimatization under standard environmental conditions of room temperature (25±2)℃, humidity (65±5)%, and 12-hour day-night cycle, experiments were conducted.
[0047] (1) Preparation of fermentation broth: Select the screened strain XBMU-SN-23 and ferment it at 37℃ for 2 days according to the optimized process parameters. During the fermentation, closely monitor the culture temperature and humidity. After the fermentation is completed, centrifuge the fermentation broth at 8000 r for 10 min at 4℃, transfer it to an autoclave and sterilize it at 100℃ for 15 min. Seal and store at 4℃.
[0048] (2) Animal experiment grouping: Sixty male mice were randomly divided into six groups according to Table 1, with 10 mice in each group. Each experimental group was weighed daily, and the XBMU-SN-23 fermentation supernatant (GABA: 300 mg / kg) was diluted to different dose gradients of 10% (30 mg / kg), 30% (90 mg / kg), and 50% (150 mg / kg) for subsequent experiments.
[0049] Table 1 Animal treatment and experimental grouping (3) Establishment of PCPA mouse insomnia model: Days 1-3 of the experiment: Except for the control group, mice were given PCPA suspension (350 mg / kg, ip) to establish an insomnia model. The control group was injected intraperitoneally with an equal volume of physiological saline for 3 consecutive days. Successful model establishment was indicated by increased activity, irritability, loss of appetite, and loss of circadian rhythm in the mice. Days 4-10 of the experiment: Mice in the DZP group (2.5 mg / kg) and the low, medium, and high dose groups were administered the corresponding drugs by gavage. The control group and the model group were administered an equal volume of physiological saline by gavage for 7 consecutive days. The experiment ended on day 11. After 12 hours of fasting but not water, the mice were euthanized by blood collection from the orbital rim.
[0050] After the experiment, the mice were dissected in accordance with ethical requirements, and their organs were weighed.
[0051] Example 6: Determination of the levels of relevant inflammatory factors in the hypothalamus and serum of mice The mouse brain tissue from Example 5 was removed, placed in cryovials, and immediately placed in liquid nitrogen. Before testing, the brain tissue should be removed and placed at 4°C. A certain amount of PBS (pH 7.4) was added, and the sample was thoroughly homogenized using a tissue homogenizer. The sample was centrifuged twice (8000 r, 10 min), and the supernatant was collected and aliquoted for testing. Then, the levels of 5-hydroxytryptamine (5-HT), interleukin-1 (IL-1), brain-derived neurotrophic factor (BDNF), and dopamine (DA) in the brain tissue of PCPA-induced insomnia mice were measured according to the ELISA kit instructions. Mouse plasma was centrifuged twice (8000 r, 10 min), and the experimental procedures were the same as above. The levels of γ-aminobutyric acid (GABA), glutamate (Glu), and melatonin (MT) in the serum of PCPA-induced insomnia mice were measured.
[0052] The results showed that the *Lactobacillus plantarum* XBMU-SN-23 of this invention could upregulate the levels of GABA, 5-HT, IL-1, and MT, and downregulate the levels of Glu and DA, thereby effectively improving sleep. See details below. Figure 7 and Figure 8 .
[0053] Example 7: Effects of XBMU-SN-23 fermentation broth on the morphology of tissues and organs in PCPA-induced insomnia mice The mouse brain tissue from Example 5 was removed and cut into 2-3 mm pieces. 3 Small pieces of mouse tissue were fixed, washed, dehydrated, impregnated with paraffin, and embedded in paraffin. The tissue was then embedded in paraffin and cut into 4 μm thick coronal sections. The pathological changes of the hippocampus tissue of insomniac mice were observed under an optical microscope (×200) after hematoxylin-eosin (HE) staining.
[0054] Results of HE staining of mouse hippocampus as follows Figure 9As shown, compared with other groups, the hippocampal neurons in the blank control group were neatly arranged and evenly distributed, with no obvious pathological damage. In the model group, the hippocampal tissue was disordered, and the neurons were loosely arranged, with significant atrophy of thalamic cell nuclei neurons. Compared with the model group, all three treatment groups showed varying degrees of repair of damage. The hippocampal neurons in the low-dose group were relatively normal, the hippocampal neurons in the medium-dose group were neatly arranged and clearly structured, while the high-dose group showed little improvement and scattered neurons. Pathological section results indicated that the GABA-rich XBMU-SN-23 fermentation broth could improve hippocampal damage in PCPA-induced insomnia mice, thereby improving sleep. The medium dose (90 mg / kg) was the most effective in improving insomnia. Histopathological sections of the hypothalamus in mice are shown in Figure 10. Compared with the model group, the hypothalamic neurons in the blank control group were abundant, intact, and evenly distributed. In contrast, the hypothalamic neurons in the PCPA model group were loosely arranged, severely deformed, and contained a large number of fragmented cells. The cells in the XBMU-SN-23 fermentation broth treatment group were neatly arranged, and the atrophied cell damage was significantly repaired. This indicates that the XBMU-SN-23 fermentation broth has a certain effect on improving the sleep quality of PCPA-induced insomnia mice.
[0055] Example 8: Detection of 5-HT in brain tissue by Western blot 1A GABA A R α1 GABA A R γ2 Receptor protein expression Brain tissue proteins from Example 5 were extracted using a total protein extraction kit. Mouse brain tissue was placed in pre-chilled RIPA lysis buffer, homogenized by sonication, and incubated in ice water for 30 min. The supernatant of the total protein sample was obtained by incubating at 12000 r / min, 4℃, for 10 min. The protein samples were then quantitatively analyzed using a BCA kit. 5-HT proteins were separated by 10% SDS-PAGE gel electrophoresis. 1A GABA A R α1 GABA A R γ2 The protein was transferred, incubated with primary antibody, washed, and incubated with secondary antibody again. ACTIN was used as an internal control protein for semi-quantitative analysis of the target protein.
[0056] The results are as follows Figure 11 As shown, it was found that GABA mainly regulates 5-HT 1A GABA A R α1 GABA A R γ2The therapeutic effect is thus achieved by regulating the amount of receptor proteins. Therefore, the *Lactobacillus plantarum* XBMU-SN-23 of this invention regulates 5-HT by producing GABA. 1A GABA A R α1 GABA A R γ2 The amount of receptor protein can thus play a role in improving sleep or treating insomnia.
[0057] The above description is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and inventive concept of the present invention, should be covered within the scope of protection of the present invention.
Claims
1. A strain of *Lactobacillus plantarum* XBMU-SN-23, characterized in that, The plant lactobacillus ( Lactiplantibacillus plantarum XBMU-SN-23 was deposited on December 19, 2025, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 37118. The deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing.
2. The *Lactobacillus plantarum* XBMU-SN-23 according to claim 1, characterized in that, The survival rate of *Lactobacillus plantarum* XBMU-SN-23 after culturing at pH 2.0 for 24 h was 65.42%, and the survival rate after culturing at 0.5% bile salt concentration for 24 h was 79.8±2.83%.
3. The use of Lactobacillus plantarum XBMU-SN-23 as described in claim 1 in the preparation of γ-aminobutyric acid.
4. A fermentation broth containing γ-aminobutyric acid, characterized in that, The method for preparing the fermentation broth containing γ-aminobutyric acid includes: The *Lactobacillus plantarum* XBMU-SN-23 of claim 1 was inoculated into a culture containing Tween 80 and Mg. 2+ and Ca 2+ In the culture medium, the inoculum size of Lactobacillus plantarum XBMU-SN-23 was 1.5%~3.5%, the initial fermentation pH was 4.0~6.0, the fermentation temperature was 35℃~40℃, and the fermentation time was 12h~60h. After fermentation, the supernatant was collected by centrifugation to obtain the fermentation broth containing γ-aminobutyric acid.
5. The fermentation broth containing γ-aminobutyric acid according to claim 4, characterized in that, In the culture medium, the addition amount of Tween 80 is 0.4% ~ 0.6% v / v, and Mg 2+ Concentrations range from 0.1 to 0.3 mg / mL, Ca 2+ The concentration is 5~15 g / mL.
6. The use of the *Lactobacillus plantarum* XBMU-SN-23 of claim 1 or the fermentation broth containing γ-aminobutyric acid of claim 4 in the preparation of products that improve sleep and / or prevent and / or treat insomnia.
7. The application according to claim 6, characterized in that, Based on the amount of γ-aminobutyric acid contained, the oral dose of the product is 80 mg to 100 mg of γ-aminobutyric acid per kg of body weight.
8. The application according to claim 6, characterized in that, The product for improving sleep and / or preventing and / or treating insomnia has at least one of the following functions: 1) Increases the level of γ-aminobutyric acid in serum; 2) Increase serum MT levels; 3) Increases the level of serotonin in brain tissue; 4) Increase the level of interleukin-1 in brain tissue; 5) Reduce serum glutamate levels; 6) Reduces the dopamine content in brain tissue.
9. The application according to claim 6, characterized in that, The product for improving sleep and / or preventing and / or treating insomnia has at least one of the following functions: 1) Increase 5-HT levels in brain tissue 1A The content; 2) Increase GABA levels in brain tissue A R α1 The content; 3) Increases GABA levels in brain tissue A R γ2 The content of.
10. A product for improving sleep and / or preventing and / or treating insomnia, characterized in that, The active ingredients of the product include *Lactobacillus plantarum* XBMU-SN-23 as described in claim 1 or the fermentation broth containing γ-aminobutyric acid as described in claim 4.
Citation Information
Cited By
Lactobacillus plantarum PB13 and its application in improving sleep function
CN122326480A
